纯度 | >85%SDS-PAGE. |
种属 | Human |
靶点 | KLRB1 |
Uniprot No | Q12918 |
内毒素 | < 0.01EU/μg |
表达宿主 | E.coli |
表达区间 | 67-225aa |
氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSMQKSSIE KCSVDIQQSR NKTTERPGLL NCPIYWQQLR EKCLLFSHTV NPWNNSLADC STKESSLLLI RDKDELIHTQ NLIRDKAILF WIGLNFSLSE KNWKWINGSF LNSNDLEIRG DAKENSCISI SQTSVYSEYC STEIRWICQK ELTPVRNKVY PDS |
预测分子量 | 21 kDa |
蛋白标签 | His tag N-Terminus |
缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于KLRB1重组蛋白的3-4条参考文献示例,涵盖结构、功能及疾病相关性研究:
---
1. **文献名称**:**"Structural basis for recognition of cellular ligands by the natural killer cell receptor KLRB1 (CD161)"**
**作者**:Hsu, Y.L., et al.
**摘要**:该研究通过X射线晶体学解析了重组KLRB1蛋白的三维结构,揭示了其与配体(如LLT1)结合的特异性位点,阐明了KLRB1在NK细胞中识别病原体相关碳水化合物的分子机制。
2. **文献名称**:**"Functional modulation of NK cells through KLRB1 receptor-ligand interactions in viral infections"**
**作者**:Rosenberg, J., et al.
**摘要**:利用重组KLRB1蛋白进行体外实验,证明其与病毒感染的细胞表面配体结合后抑制NK细胞活性,提示KLRB1在抗病毒免疫中的调节作用可能通过负向信号通路实现。
3. **文献名称**:**"Recombinant KLRB1 binds to lectin-like ligands and regulates T cell cytokine production"**
**作者**:Aldemir, H., et al.
**摘要**:在哺乳动物细胞中高效表达功能性重组KLRB1蛋白,证实其与LLT1的相互作用可激活T细胞内的共刺激信号,促进IL-17等细胞因子分泌,为Th17相关疾病提供机制依据。
4. **文献名称**:**"Targeting KLRB1 in colorectal cancer: Recombinant protein blocks tumor-associated immunosuppression"**
**作者**:Fergusson, J.R., et al.
**摘要**:研究显示,重组KLRB1蛋白可通过竞争性结合肿瘤微环境中的配体,逆转CD8+ T细胞耗竭,增强抗肿瘤免疫反应,为癌症免疫治疗提供新策略。
---
**备注**:上述文献信息为示例性质,实际研究中请通过PubMed或Web of Science等数据库核实具体文献。KLRB1(CD161)的研究多聚焦于其免疫调节功能,重组蛋白常被用于配体互作、信号通路及疾病模型研究。
KLRB1. also known as CD161 or NKR-P1A, is a transmembrane protein encoded by the *KLRB1* gene and belongs to the C-type lectin-like receptor family. It is primarily expressed on natural killer (NK) cells, subsets of T cells (e.g., mucosal-associated invariant T cells, MAIT cells), and innate lymphoid cells. Structurally, KLRB1 contains a extracellular C-type lectin-like domain, a stalk region, a transmembrane domain, and a cytoplasmic tail lacking intrinsic signaling motifs. It functions as a receptor that interacts with lectin-like ligands, such as CLEC2D (LLT1), to modulate immune cell activity.
KLRB1 plays dual roles in immune regulation. It can activate NK cell cytotoxicity upon ligand binding in certain contexts, but more commonly, it delivers inhibitory signals by recruiting phosphatases like SHP-1/2. dampening immune responses. This receptor is implicated in balancing immune tolerance and defense, particularly at mucosal sites. It also serves as a marker for specific T cell subsets, including type 17 and regulatory T cells, linking it to autoimmune diseases, infections, and cancer immunology.
Recombinant KLRB1 protein, produced via bacterial or mammalian expression systems, is widely used to study ligand-receptor interactions, immune checkpoint pathways, and therapeutic targeting. Its applications span structural analysis, inhibitor screening, and functional assays exploring NK/T cell regulation. In cancer research, KLRB1 is investigated as a potential immune checkpoint, with blocking strategies aimed at enhancing anti-tumor immunity. Additionally, its role in microbial responses and tissue homeostasis underscores its relevance in infectious and inflammatory diseases.
Studies of KLRB1 recombinant protein continue to advance understanding of immune modulation and therapeutic interventions in immuno-oncology and autoimmune disorders.
×